Theratechnologies Inc
Officers & Directors
Paul Lévesque serves as President and Chief Executive Officer of the Corporation. Marie-Noël Colussi, Vice President, Finance, joined the company in 1997. She is 56 years old, holds a degree in business administration from Université du Québec à Montréal, is a member of the Quebec Chartered Professional Accountant Order, and has expertise in accounting, auditing, control, and taxation, with a focus on research and development.
Philippe Dubuc, Senior Vice President and Chief Financial Officer, joined on February 24, 2016. He is 58 years old and has over 25 years of experience in investment banking within the healthcare sector and management. His career includes roles as a management consultant at Groupe Secor, Managing Director of Investment Banking at National Bank Financial, and founder of a manufacturing company. He holds an M.B.A. from McGill University and a B.Comm. from Concordia University.
André Dupras, Vice President, Human Resources, joined on May 31, 2021. He is 61 years old and has more than 25 years of human resources experience. His previous positions include Vice President, Human Resources at Clementia Pharmaceuticals and leadership roles at Pfizer Canada. He has also worked at Bombardier Aerospace, Aon Hewitt, and Réno-Dépôt. He holds a Master’s Degree in Management Science (Human Resources), a Bachelor’s Degree in Administration (Marketing and Human Resources), and is a member of the Order of Certified Human Resources Professionals.
Jocelyn Lafond, General Counsel and Corporate Secretary, joined on April 16, 2007. He is 57 years old and has over 20 years of experience in corporate and securities law. He holds a law degree from Université Laval and a Master’s Degree in Law from the University of Toronto. He has been a member of the Barreau du Québec since 1992 and was previously a partner at Fasken Martineau DuMoulin LLP.
John Leasure, Global Commercial Officer, joined on March 29, 2021. He is 60 years old and has extensive experience in sales, marketing, operations, and general management in the U.S. and internationally. He has expertise in managing brands across product life cycles and has launched numerous products in various therapeutic areas. He spent 30 years at Pfizer, leading teams in Anti-infectives, Inflammation, Immunology, and Oncology, most recently overseeing the Oncology business in Canada.
Theratechnologies Inc currently has 88 employees.
News about Theratechnologies Inc Key Personnel |
In an era where the healthcare landscape is constantly evolving, Theratechnologies Inc. finds itself at a critical juncture, grappling with challenges and opportunities that could shape its future. The Montreal-based biopharmaceutical company, known for its innovative therapies, recently announced a significant supply shortage of its product, EGRIFTA SV (tesamorelin for injection), expected to impact patients at the mid-January 2025 mark. This anticipated shortage stems from a voluntary shutdown of a contract manufacturing facility in late 2024, a move that has led to reported stockouts in several U.S. pharmacies. The urgency surrounding EGRIFTA SV s supply issues highlights a broader concern within the phar...
|
MONTREAL, Dec. 10, 2024 — Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies, announced today that the United States Food and Drug Administration (FDA) has designated a Prescription Drug User Fee Act (PDUFA) goal date of March 25, 2025, for its supplemental Biologics License Application (sBLA) concerning the F8 formulation of tesamorelin. This pivotal date marks a significant milestone for the company as it seeks to advance its product offering within the competitive landscape of biopharmaceutical therapies.The F8 formulation of tesamorelin is a synthetic HGH-releasing hormone that has shown promise in trea...
|
In a recent development, biopharmaceutical company Theratechnologies Inc. has received a refusal to file letter (RTF) from the United States Food and Drug Administration (FDA) regarding the company s supplemental Biologics License Application (sBLA) for an intramuscular (IM) method of administration for the maintenance dose of Trogarzo (ibalizumab-uiyk). This setback comes as the company recorded a significant net loss in the past year, raising concerns about its financial stability. This article aims to outline the facts surrounding these events and assess their impact on Theratechnologies.
I. The FDA Refusal to File Letter:
On February 27, 2024, Theratechnologies made the announcement tha...
|
|
|
